SCHEMBL307883

SCHEMBL307883

CC1(C)C2=C(Cl)C(=O)C(Cl)=CC2=Nc2ccc(OP(=O)(O)O)cc21

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
INPPL1 O15357 1/20 0.33
INPP5A Q14642 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL29552244 0.99 INPPL1 (0.33) INPPL1INPP5A
Ammonia Solution, Strong SCHEMBL1868933 0.99 INPPL1 (0.33) INPPL1INPP5A
Ammonia Solution, Strong SCHEMBL1868935 0.99 INPPL1 (0.33) INPPL1INPP5A
SCHEMBL20777534 0.84 GLA (0.33)
Phosphoric Acid SCHEMBL3417079 0.83
SCHEMBL18634052 0.82 ALDH1A1 (0.32)
SCHEMBL29931019 0.80 PDE3B (0.31)
SCHEMBL29446026 0.78 CASP3 (0.35)
SCHEMBL16616806 0.77 ALDH1A1 (0.33)
SCHEMBL30433736 0.77 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10605803-B2 Composition for enzyme immunoassay using immunofluorescence and uses thereof BIOMERIEUX (FR) 2020-03-31 US claimed
EP-3207371-B1 COMPOSITION FOR ENZYME IMMUNOASSAY USING IMMUNOFLUORESCENCE AND USES THEREOF BIOMERIEUX SA (FR) 2018-12-12 EP claimed
US-20170241994-A1 COMPOSITION FOR ENZYME IMMUNOASSAY USING IMMUNOFLUORESCENCE AND USES THEREOF BIOMERIEUX (FR) 2017-08-24 US claimed
EP-3207371-A1 COMPOSITION FOR ENZYME IMMUNOASSAY USING IMMUNOFLUORESCENCE AND USES THEREOF Biomérieux (FR) 2017-08-23 EP claimed
WO-2016059351-A1 COMPOSITION FOR ENZYME IMMUNOASSAY USING IMMUNOFLUORESCENCE AND USES THEREOF bioMérieux (FR) 2016-04-21 WO claimed
US-20140349893-A1 LABELING OF IMMOBILIZED PROTEINS USING DIPYRROMETHENEBORON DIFLUORIDE DYES Life Technologies Corporation (US) 2014-11-27 US claimed
US-20130288270-A1 CHEMILUMINESCENT ENZYME ASSAY METHOD AND APPARATUS LUMINESCENT MD. LLC (US) 2013-10-31 US claimed
EP-1725676-B1 MEASURING CONTAMINATION MYCOMETER AS (DK) 2012-04-25 EP claimed
JP-4643262-B2 2011-03-02 JP claimed
JP-4643263-B2 2011-03-02 JP claimed
WO-2004020604-A2 ALLELE SPECIFIC PRIMER EXTENSION AMERSHAM BIOSCIENCES CORP (US) 2004-03-11 WO claimed
US-20040048301-A1 Allele specific primer extension GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2004-03-11 US claimed
WO-2004020603-A2 ANALYTE DETECTION AMERSHAM BIOSCIENCES CORP (US) 2004-03-11 WO claimed
US-20030162213-A1 Terminal-phosphate-labeled nucleotides and methods of use GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-08-28 US claimed
US-20030124576-A1 Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-07-03 US claimed
US-20030096253-A1 Single nucleotide amplification and detection by polymerase GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-05-22 US claimed
US-20030077610-A1 Terminal-phosphate-labeled nucleotides and methods of use GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-04-24 US claimed
WO-2003020984-A2 TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed
WO-2003020891-A2 SINGLE NUCLEOTIDE AMPLIFICATION AND DETECTION BY POLYMERASE AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed
WO-2003020734-A2 LABELED NUCLEOSIDE POLYPHOSPHATES AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124576-A1 Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases PNP, RNGTT, MTAP INPPL1 44/4885INPP5A 155/4885
US-20030077610-A1 Terminal-phosphate-labeled nucleotides and methods of use RNGTT, DNTT, PNP INPPL1 69/4885INPP5A 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.